Cytarabine Hydrochloride: A Key Pharmaceutical Intermediate for Leukemia Treatment

Discover the essential role of Cytarabine Hydrochloride in combating leukemia and advancing cancer therapies.

Get a Quote & Sample

Key Advantages

Uncompromised Purity

Achieve superior therapeutic outcomes with our high purity Cytarabine Hydrochloride (>99%), ensuring minimal impurities and maximum efficacy in your formulations.

Certified Quality Assurance

Rely on our stringent quality control, evidenced by GMP, HSE, ISO 9001, USP, and BP certifications, guaranteeing a pharmaceutical intermediate for leukemia treatment that meets global standards.

Reliable Supply Chain

Benefit from a consistent and dependable supply of Cytarabine HCl powder, supporting your production needs without interruption for your chemotherapy drug development.

Key Applications

Acute Myeloid Leukemia (AML) Treatment

Cytarabine Hydrochloride is a primary component in regimens targeting AML, playing a critical role in reducing leukemia cell counts and achieving remission.

Acute Lymphocytic Leukemia (ALL) Therapy

Its antimetabolite properties are essential for treating ALL, disrupting cancer cell DNA synthesis and aiding in patient recovery.

Chronic Myelogenous Leukemia (CML) Support

While other treatments exist, Cytarabine Hydrochloride can be part of comprehensive strategies for managing CML, contributing to disease control.

DNA Synthesis Inhibition in Oncology

As a potent inhibitor of DNA synthesis, it serves as a crucial intermediate for developing advanced antineoplastic agents.